That's a turn around on your part, and long overdue
I've always been on the record as supporting this. Trade US rights for cash and a %royalty. Keep ROW. Eventually sell ROW and US royalty % en bloc, hopefully to the same entity that buys the US rights. Immediate cash in bank, no need for further cap raises and sp rises and immediate start on FDA by a committed partner.
You've always been negative about it.
OSL will never have the capital to undertake pivotal US FDA trials for ca pancreas.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.025(2.43%) |
Mkt cap ! $14.29M | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.05 | $1.00 | $41.05K | 40.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 1249 | 1 |
View Market Depth
| Last trade - 15.47pm 20/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |